Mouse interferon or the induction of mouse interferon with polyriboinosinic acid-polyribocytidylic acid significantly protected mice against herpes simplex and ectromelia viral infections. When polyriboinosinic acid-polyribocytidylic acid was administered 24 h before herpes simplex or ectromelia viral infection and mouse interferon was administered shortly before and 24 h after infection, a combined protective effect against either herpes simplex or ectromelia viral infection in mice was evident. There was a significant decrease in the mortality rate with the combined tre4tment as compared either with the rate in groups treated with interferon or polyriboinosinic acid-polyribocytidylic acid.
It is certain that interferon can protect animals and humans against many viral diseases (10), and recently its clinical application has greatly increased (4) due to large-scale production and purification for such use (1, 6). However, only a limited number of patients have benefited to date, since it is still difficult to produce or purchase it in sufficient quantity.
Interferon promises to be extensively applied to various viral diseases and cancers, and other applications are possible because of its many biological activities and very low toxicity. Most patients can tolerate large doses. It is, however, easier at present to obtain sigaiificant interferon levels in the body by an appropriate inducer than by exogenous administration. But interferon induction is also associated with problems of hyporeactivity (tolerance) (12) , toxicity (2, 9), and variation in inducibility among individuals.
It seemed possible that a combination of interferon administration and its induction might circumvent some of these problems, and the present study was found with interferon or interferon induction alone and with a combination of the two, but the protection provided by the latter was not as great as that seen with the protocol in Table 2 .
There was no indication in any of these experiments for toxicity due to the combined treatment regimen in controls in the absence of virus infection.
The present study illustrates the enhanced protective effect ofthe combination ofinterferon and its induction by polyriboinosinic acid-polyribocytidylic acid against herpes simplex virus and ectromelia virus infections. Nothing has yet been reported about such combination therapy against viral infections, although there are reports concerning combinations of interferon and other drugs. Lerner and Bailey (7, 8) showed that 9-,B-D-arabinofuranosyladenine and human interferon are synergistically effective against herpes simplex virus type 1, but only additively effective against herpes simplex virus type 2, in vitro, and such combined effects were also found in vivo. A combined injection of ammonium 5-tungsto-2-antimoniate and mouse interferon reduced the mortality rate and prolonged the mean survival time of mice infected with encephalomyocarditis virus (11) , and a similar effect was observed with isoprinosine and interferon (3).
It may be important to develop the combined therapy in clinical application in order to reduce the toxic effects associated with interferon and its induction. 
